Search our Database of Scientific Publications and Authors

I’m looking for a

    3420 results match your criteria Hyperphosphatemia

    1 OF 69

    Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
    Pharmazie 2017 Feb;72(2):118-122
    Sucroferric oxyhydroxide (SFOH) is a non-calcium, iron-based phosphate binder indicated for the treatment of hyperphosphatemia in adult dialysis patients. Studies in Japan about the side effects of SFOH treatment indicate that the incidence of diarrhea (25%) is greater while that of constipation (2.9%) is lesser in comparison to that observed upon treatment with an existing phosphate binder. Read More

    Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.
    Int J Nephrol Renovasc Dis 2018 5;11:69-80. Epub 2018 Feb 5.
    Division of Nephrology, Hennepin County Medical Center, University of Minnesota, Minneapolis, MN.
    Secondary hyperparathyroidism (SHPT) is common in patients receiving maintenance hemodialysis and is associated with adverse outcomes. Currently, SHPT is managed by reducing circulating levels of phosphate with oral binders and parathyroid hormone (PTH) with vitamin D analogs and/or the calcimimetic cinacalcet. Etelcalcetide, a novel calcimimetic administered intravenously (IV) at the end of a hemodialysis treatment session, effectively reduces PTH in clinical trials when given thrice weekly. Read More

    Rapid whole genome sequencing identifies a novel AIRE variant associated with Autoimmune Polyendocrine Syndrome Type 1.
    Cold Spring Harb Mol Case Stud 2018 Feb 1. Epub 2018 Feb 1.
    Rady Children's Institute for Genomic Medicine.
    Autoimmune polyendocrine syndrome type 1 (APS1; OMIM #240300), also referred to as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare monogenic disorder caused by mutations in the autoimmune regulator (AIRE) gene. APS1 is classically characterized by a triad of chronic mucocutaneous candidiasis, autoimmune hypoparathyroidism, and autoimmune adrenocortical insufficiency. We report a five-year-old female who presented with symptoms of tetany due to hypocalcemia and was subsequently found to be secondary to hypoparathyroidism. Read More

    Pseudohypoparathyroidism type 1B in a patient conceived by in vitro fertilization: another imprinting disorder reported with assisted reproductive technology.
    J Assist Reprod Genet 2018 Feb 7. Epub 2018 Feb 7.
    Pediatric Endocrinology, Mercy Hospital St. Louis, St. Louis, MO, USA.
    Pseudohypoparathyroidism type 1B (PHP1B) is characterized by renal tubular resistance to parathyroid hormone (PTH) leading to hyperphosphatemia, hypocalcemia, elevated PTH, and hyperparathyroid bone changes. PHP1B is an imprinting disorder that results from loss of methylation at the maternal GNAS gene, which suppresses transcription of the alpha subunit of the stimulatory G protein of the PTH receptor. Emerging evidence supports an association between assisted reproductive technologies (ART) and imprinting disorders; however, there is currently little evidence linking PHP1B and ART. Read More

    [Pharmacological, pharmaceutical and clinical profiles of sucroferric oxyhydroxide (P-TOLChewable Tab. 250 mg, 500 mg), a therapeutic agent for hyperphosphatemia].
    Nihon Yakurigaku Zasshi 2018 ;151(2):75-86
    Clinical Administration, Clinical Research Department, Kissei Pharmaceutical Co., Ltd.
    Sucroferric oxyhydroxide (P-TOLchewable tablets, 250 and 500 mg) is a phosphate binder for oral use; it is composed of polynuclear iron (III)-oxyhydroxide, sucrose, and starches, and is currently indicated for alleviating hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The results of non-clinical pharmacological studies have suggested that P-TOL consistently decreases serum phosphorus levels in the aqueous environment at pH levels similar to those in the gastrointestinal tract, thereby suppressing the progression of secondary hyperparathyroidism, aberrant calcification, and abnormal bone metabolism associated with hyperphosphatemia. Since the diameter of the P-TOL tablet exceeds 15 mm, it is manufactured with a doughnut-shape to minimize choking hazards. Read More

    Phosphate is a potential biomarker of disease severity and predicts adverse outcomes in acute kidney injury patients undergoing continuous renal replacement therapy.
    PLoS One 2018 7;13(2):e0191290. Epub 2018 Feb 7.
    Department of Internal Medicine, College of Medicine, Institute of Kidney Disease Research, Yonsei University, Seoul, Korea.
    Hyperphosphatemia is associated with mortality in patients with chronic kidney disease, and is common in critically ill patients with acute kidney injury (AKI); however, its clinical implication in these patients is unknown. We conducted an observational study in 1144 patients (mean age, 63.2 years; male, 705 [61. Read More

    Phosphate Removal During Conventional Hemodialysis: a Decades-Old Misconception.
    Kidney Blood Press Res 2018 Jan 31;43(1):110-114. Epub 2018 Jan 31.
    Department of Medicine, Renal Division, Universidade de São Paulo, São Paulo, Brazil.
    Background/aims: Hyperphosphatemia is associated with high mortality rate in patients on dialysis. Conventional hemodialysis (HD) is a limit technique in removing phosphate (P). There is a widespread belief that P is removed mainly in the first hour of HD. Read More

    [Chronic Kidney Disease - Update 2018].
    Dtsch Med Wochenschr 2018 Feb 6;143(3):169-173. Epub 2018 Feb 6.
    Medizinische Klink III, Nephrologische Abteilung, Klinikum Coburg.
    SGLT2-INHIBITION IN DIABETIC AND NON-DIABETIC KIDNEY DISEASE:  The CANVAS Program Collaborative Group study confirmed nephroprotective actions by canagliflocin comparable to empagliflozin as published in the EMPA-REG Outcome study. Treatment with Liraglutide (LEADER study) also suggests nephroprotection via albuminuria reduction a decreased eGFR decline in subgroups and depending on stages of diabetic nephropathy. KDIGO CKD-MBD GUIDELINE UPDATE 2017:  In July 2017, an update of the KDIGO (Kidney Disease: Improving Global Outcomes) 2009 guideline on diagnostic and treatment chronic kidney disease - mineral and bone disorders (CKD-MBD) was published. Read More

    Hypophosphatasia: the contribution of imaging.
    Arch Pediatr 2017 May;24(5S2):5S74-5S79
    Centre de référence pour les maladies rares du métabolisme du calcium et du phosphore, filière OSCAR; unité d'endocrinologie, maladies osseuses, génétique et gynécologie, hôpital des enfants, CHU de Toulouse, TSA 70034, 31059 Toulouse Cedex 09, France; Centre de physiopathologie de Toulouse-Purpan, CPTP, INSERM UMR 1043, université de Toulouse-Paul-Sabatier, 31059 Toulouse, France. Electronic address:
    Radiography and imaging are necessary for the diagnosis of hypophosphatasia (HPP) at all stages of life, from the antenatal period to the complications of adulthood, and in the forms of variable severity. The consequences of alkaline phosphatase activity deficiency, namely defective mineralization and bone fragility, may be detected by radiological tools and share features that distinguish them from other diseases responsible for mineralization defects. Radiography and imaging are also fundamental for the screening and diagnosis of the complications of HPP, some of which are related to the episodes of hypercalcemia and hyperphosphatemia (nephrocalcinosis). Read More

    Perinatal and infantile hypophosphatasia: clinical features and treatment.
    Arch Pediatr 2017 May;24(5S2):5S61-5S65
    Centre de référence maladies osseuses constitutionnelles, Institut Imagine, université Paris-Descartes-Sorbonne-Paris Cité, hôpital Necker-Enfants malades, 149, rue de Sèvres, 75015 Paris, France.
    Hypophosphatasia (HPP) is a rare hereditary disease characterized by defective skeletal mineralization, and with a broad severity spectrum. The perinatal forms, lethal and non-lethal, are associated with severe neonatal respiratory distress, potential seizures, hypotrophy and marked hypotonia. The diagnosis is rapidly suggested by a combination of typical radiological signs, hypercalcemia, hyperphosphatemia and low alkaline phosphatase (ALP) activity. Read More

    Relation of the Brugada Phenocopy to Hyperkalemia (from the International Registry on Brugada Phenocopy).
    Am J Cardiol 2017 Dec 29. Epub 2017 Dec 29.
    Department of Medicine, Queen's University, Kingston, Ontario, Canada. Electronic address:
    Brugada phenocopies (BrPs) are clinical entities that differ in etiology from true congenital Brugada syndrome but have identical electrocardiographic (ECG) patterns. Hyperkalemia is known to be one of the causes of BrP. The aim of this study was to determine the clinical characteristics and evolution of hyperkalemia-induced BrP. Read More

    Pulse versus daily oral Alfacalcidol treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized controlled trial.
    Int J Nephrol Renovasc Dis 2018 15;11:25-32. Epub 2018 Jan 15.
    Public Health Department, College of Health Sciences, Qatar University, Doha, Qatar.
    Background: Secondary hyperparathyroidism is a common complication of chronic kidney disease and is managed using vitamin D replacement therapy. Very few studies have examined the effectiveness of pulse alfacalcidol therapy in comparison to daily oral alfacalcidol therapy in suppressing serum parathyroid hormone (PTH) levels in hemodialysis patients. The aim of this randomized controlled trial was to replicate the findings of prior studies comparing effectiveness of pulse oral alfacalcidol therapy versus daily oral alfacalcidol therapy in suppressing PTH after 13 weeks of therapy using a Palestinian sample of hemodialysis patients, and to identify demographic and biomedical characteristics of patients that are independently associated with PTH levels. Read More

    Classic and Non-Classic Features in Pseudohypoparathyroidism: Case Study and Brief Literature Review.
    Cureus 2017 Nov 26;9(11):e1878. Epub 2017 Nov 26.
    Assistant Clinical Professor of Internal Medicine, West Virginia University School of Medicine.
    Pseudohypoparathyroidism is a rare condition that is due to a defect in the stimulatory G-protein coupled receptor, resulting in end-organ resistance to parathyroid hormone. Hereditary forms of pseudohypoparathyroidism present with certain classic features such as obesity, short stature, brachydactyly, and intellectual disability. Constellation of these physical features is known as Albright's hereditary osteodystrophy. Read More

    (Epi)genotype-Phenotype Analysis in 69 Japanese Patients With Pseudohypoparathyroidism Type I.
    J Endocr Soc 2018 Jan 21;2(1):9-23. Epub 2017 Nov 21.
    Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan.
    Context: Pseudohypoparathyroidism type I (PHP-I) is divided into PHP-Ia with Albright hereditary osteodystrophy and PHP-Ib, which usually shows no Albright hereditary osteodystrophy features. Although PHP-Ia and PHP-Ib are typically caused by genetic defects involvingsubunit of the stimulatory G protein (Gs)-codingexons and methylation defects of thedifferentially methylated regions (DMRs) on the maternal allele, respectively, detailed phenotypic characteristics still remains to be examined.

    Objective: To clarify phenotypic characteristics according to underlying (epi)genetic causes. Read More

    Effect of variations in dietary Pi intake on intestinal Pi transporters (NaPi-IIb, PiT-1, and PiT-2) and phosphate-regulating factors (PTH, FGF-23, and MEPE).
    Pflugers Arch 2018 Jan 25. Epub 2018 Jan 25.
    Medical School, Division of Nephrology, Universidade de São Paulo, São Paulo, Brazil.
    Hyperphosphatemia is a common condition in patients with chronic kidney disease (CKD) and can lead to bone disease, vascular calcification, and increased risks of cardiovascular disease and mortality. Inorganic phosphate (P) is absorbed in the intestine, an important step in the maintenance of homeostasis. In CKD, it is not clear to what extent Pabsorption is modulated by dietary P. Read More

    Influence of Carnicor, Venofer, and Sevelamer on the levels of genotoxic damage in end-stage renal disease patients.
    Environ Mol Mutagen 2018 Jan 23. Epub 2018 Jan 23.
    Grup de Mutagènesi, Departament de Genètica i de Microbiologia, Edifici Cn, Universitat Autònoma de Barcelona, Bellaterra, Cerdanyola del Vallès, 08193, Spain.
    End-stage renal disease (ESRD) patients present high levels of phosphorus and calcium products in serum, which contribute to the development of vascular calcification and cardiovascular disease, and to low iron stores and carnitine deficiency. For these reasons, ESRD patients are generally supplemented with different medicines. Some of the most common treatments include the use of Carnicor, Venofer, and Sevelamer drugs. Read More

    Defective Interplay Between mTORC1 Activity and Endoplasmic Reticulum Stress-Unfolded Protein Response in Uremic Vascular Calcification.
    Am J Physiol Renal Physiol 2018 Jan 10. Epub 2018 Jan 10.
    Division of Endocrinology, Jewish General Hospital,, McGill University, Montreal, Canada;, Canada.
    Vascular calcification increases the risk of cardiovascular disease and death in patients with chronic kidney disease (CKD). Increased activity of the mammalian target of rapamycin complex 1 (mTORC1) and endoplasmic reticulum (ER) stress-unfolded protein response (UPR) are reported to partake independently in the pathogenesis of vascular calcification in CKD. However, the association between mTORC1 activity and ER stress-UPR remains unknown. Read More

    Elevated Phosphate Levels Trigger Autophagy-Mediated Cellular Apoptosis in H9c2 Cardiomyoblasts.
    Cardiorenal Med 2017 Dec 30;8(1):31-40. Epub 2017 Sep 30.
    Graduate Institute of Basic Medical Science, China Medical University, Taichung.
    Background/aim: In chronic kidney disease (CKD), kidneys fail to maintain phosphorus homeostasis in serum. Elevated phosphorus levels in serum have been associated with cardiovascular diseases in CKD patients and in normal individuals. In this study, we evaluated the level of autophagy- and apoptosis-related markers under different concentrations of hyperphosphate in myocardial cells. Read More

    Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.
    Kidney Int Rep 2018 Jan 6;3(1):185-192. Epub 2017 Oct 6.
    Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
    Introduction: In this phase III, open-label, single-arm, multi-center 12-week study, we evaluated the efficacy and safety of combination therapy with sucroferric oxyhydroxide (PA21) and calcium carbonate for hemodialysis patients with hyperphosphatemia.

    Methods: We enrolled 35 subjects aged ≥ 20 years with end-stage kidney disease and serum phosphorus 3.5-6. Read More

    NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.
    Kidney Int Rep 2018 Jan 12;3(1):73-80. Epub 2017 Aug 12.
    Astellas Pharma Europe BV, Leiden, Netherlands.
    Introduction: Serum phosphate levels are insufficiently controlled in many patients with end-stage renal disease (ESRD), and novel therapeutic strategies are needed. Blocking intestinal phosphate absorption mediated by sodium-dependent phosphate co-transporter type 2b (NPT-IIb) holds promise; thus, we evaluated the efficacy, safety, tolerability, and pharmacokinetics of the novel and specific small molecule NPT-IIb inhibitor ASP3325 for the first time in humans.

    Methods: We conducted a randomized, double-blind, placebo-controlled, phase 1a single (n = 88) and multiple (n = 36) ascending dose study in healthy subjects, and a randomized, open-label, uncontrolled, phase 1b study in hyperphosphatemic ESRD patients on hemodialysis (single oral dose, n = 5; multiple oral doses, n = 17). Read More

    Extracellular Vesicles As Mediators of Cardiovascular Calcification.
    Front Cardiovasc Med 2017 11;4:78. Epub 2017 Dec 11.
    Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital, Boston, MA, United States.
    Involvement of cell-derived extracellular particles, coined as matrix vesicles (MVs), in biological bone formation was introduced by Bonucci and Anderson in mid-1960s. In 1983, Anderson et al. observed similar structures in atherosclerotic lesion calcification using electron microscopy. Read More

    EPIC Trial: education programme impact on serum phosphorous control in CKD 5D patients on hemodialysis.
    J Bras Nefrol 2017 Oct-Dec;39(4):398-405
    Universidade de São Paulo, Instituto de Ciências Biomédicas, Departamento de Farmacologia, São Paulo - SP, Brazil.
    Introduction: In stage 5D chronic kidney disease (CKD 5D) patients, the encouragement of treatment adherence by health professionals is a significant clinical challenge.

    Objectives: This study evaluates the impact of a nutritional education programme on hyperphosphatemia, utilizing the transtheoretical model of behavior change (TMBC).

    Subjects And Methods: A prospective interventional study comprising 179 CKD 5D patients with hypophosphatemia. Read More

    A case of tumor lysis syndrome and acute renal failure associated with elotuzumab treatment in multiple myeloma.
    Clin Nephrol Case Stud 2017 22;5:78-81. Epub 2017 Nov 22.
    University of Michigan Health System, Department of Internal Medicine, Division of Nephrology, A. Alfred Taubman Health Care Center, Ann Arbor, MI, USA.
    Renal dysfunction is a common comorbidity of multiple myeloma. However, tumor lysis syndrome is a rare cause of renal dysfunction in multiple myeloma. Elotuzumab is a newly US FDA-approved monoclonal antibody used in the treatment of refractory multiple myeloma. Read More

    Hyperphosphatemia is associated with high mortality in severe burns.
    PLoS One 2018 9;13(1):e0190978. Epub 2018 Jan 9.
    Kidney Research Center, Department of Nephrology, Change Gung Memorial Hospital, Linkou branch, Taoyuan, Taiwan.
    Introduction: Phosphate level is often deranged during acute illness, regardless of the presence of kidney injury or not. A few studies described that hypophosphatemia may associated with outcome in patients admitted to the burn unit, but the literatures for hyperphosphatemia is limited. Our study aims to evaluate if hyperphosphatemia, one of the sign of severe tissue damage or kidney injury, will associate with mortality of patients with severe burns. Read More

    Genetic background influences cardiac phenotype in murine chronic kidney disease.
    Nephrol Dial Transplant 2017 Dec 22. Epub 2017 Dec 22.
    Division of Nephrology and Hypertension, Department of Medicine, Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
    Background: Levels of fibroblast growth factor 23 (FGF23) increase early in chronic kidney disease (CKD) and are independently associated with left ventricular hypertrophy (LVH), heart failure and death. Experimental models of CKD with elevated FGF23 and LVH are needed. We hypothesized that slow rates of CKD progression in the Col4a3 knockout (Col4a3KO) mouse model of CKD would promote development of LVH by prolonging exposure to elevated FGF23. Read More

    [Hypophosphatemia is associated with poor prognosis of critically ill patients: a meta-analysis of 1 555 patients].
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2018 Jan;30(1):34-40
    Department of Intensive Care Unit, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou, China (Liu B, Cheng YM, Shen F, Wang YH, Wu YQ); Department of Intensive Care Unit, Second Affiliated Hospital of Guizhou Medical University, Kaili 556000, Guizhou, China (Yao L); Department of Intensive Care Unit, Fourth People's Hospital of Zhenjiang City, Zhenjiang 212000, Jiangsu, China (Liu YQ); Department of Oncology, Mineral Hospital of Liupanshui City, Liupanshui 553000, Guizhou, China (Gou XB). Corresponding author: Shen Feng, Email:
    Objective: To evaluate the relationship between hypophosphatemia and prognosis in critically ill patients.

    Methods: Some hypophosphatemia-associated prospective or retrospective clinical cohort studies were searched through CNKI, Wanfang Data, PubMed, Embase, Cochrane library, and Google Scholar English database respectively, with the guidance of these key words such as hypophosphatemia, intensive care, prognosis and fatality rate. The articles were concerned about the correlation between hypophosphatemia and the prognosis of patients in intensive care unit (ICU). Read More

    Exogenous BMP7 in aortae of rats with chronic uremia ameliorates expression of profibrotic genes, but does not reverse established vascular calcification.
    PLoS One 2018 5;13(1):e0190820. Epub 2018 Jan 5.
    Nephrological Department P, Rigshospitalet, Copenhagen, Denmark.
    Hyperphosphatemia and vascular calcification are frequent complications of chronic renal failure and bone morphogenetic protein 7 (BMP7) has been shown to protect against development of vascular calcification in uremia. The present investigation examined the potential reversibility of established uremic vascular calcification by treatment of uremic rats with BMP7. A control model of isogenic transplantation of a calcified aorta from uremic rats into healthy littermates examined whether normalization of the uremic environment reversed vascular calcification. Read More

    Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
    Ren Fail 2018 Nov;40(1):38-42
    a Department of Internal Medicine, Oshima Clinic , Saitama , Japan.
    This study aimed to investigate the association of gastrointestinal (GI) adverse events of cinacalcet with gallstones in the hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). A total of 23 HD patients under the treatment with cinacalcet and 101 control patients were enrolled in this cross-sectional study. We investigated the prevalence of gallstones and the association of GI adverse events of cinacalcet with gallstones. Read More

    Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Ren Fail 2018 Nov;40(1):15-21
    a Department of Nephrology , Zhongshan Hospital, Xiamen University , Xiamen , Fujian , China.
    Background: This study investigated the therapeutic effect of intensive phosphorus-lowering therapy on intact-parathyroid hormone (iPTH) levels in hemodialysis patients.

    Methods: Ninety-five hemodialysis patients with serum phosphorus ≥1.78 mmol/L and iPTH ≥300 pg/dL were apportioned to either the treatment or control group (n = 43 and 52, respectively) based on patient commitment to treatment. Read More

    A systematic review on the efficacy and safety of PA21 versus sevelamer in dialysis patients.
    Int Urol Nephrol 2018 Jan 2. Epub 2018 Jan 2.
    Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
    Aim: To evaluate the efficacy and safety of PA21 versus sevelamer in dialysis patients.

    Methods: We searched Medline, Embase, Science Citation Index, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing PA21 and sevelamer in dialysis patients.

    Results: Four studies were included. Read More

    The Importance of Networking in Pseudohypoparathyroidism: EuroPHP Network and Patient Support Associations.
    Pediatr Endocrinol Rev 2017 Nov;15(Suppl 1):92-97
    Molecular (Epi)Genetics Laboratory, BioAraba National Health Institute, Hospital Universitario Araba-Txagorritxu, Vitoria-Gasteiz, Spain.
    Pseudohypoparathyroidism is a rare endocrine disorder with an estimated prevalence of 1/100,000. It is characterized by hypocalcemia and hyperphosphatemia in the absence of vitamin D deficiency or impaired renal function. Research studies during the last 20 years have led to the identification of the molecular underlying cause of the disease, the characterization of the clinical and biochemical characteristics and the observation of an overlap between genetic and clinical manifestations. Read More

    Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease.
    Oncotarget 2017 Dec 20;8(63):107283-107294. Epub 2017 Oct 20.
    Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
    Ferric citrate has been reported to have the potential to reduce phosphate and increase iron availability in patients with chronic kidney disease. In the present study, we evaluated its safety and efficacy in phosphate reduction and iron supplementation in chronic kidney disease stage 3-5 requiring dialysis patients. We systematically searched for clinical trials published in PubMed, Medline, and Cochrane databases. Read More

    Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification.
    J Vis Exp 2017 Nov 20(129). Epub 2017 Nov 20.
    Developmental Biology, The Roslin Institute and R(D)SVS, University of Edinburgh.
    Calcific aortic valve disease (CAVD) is characterized by the progressive thickening of the aortic valve leaflets. It is a condition frequently found in the elderly and end-stage renal disease (ESRD) patients, who commonly suffer from hyperphosphatemia and hypercalcemia. At present, there are no medication therapies that can stop its progression. Read More

    A Randomized, Double-Blind, Crossover Pilot Trial of Rice Endosperm Protein Supplementation in Maintenance Hemodialysis Patients.
    Sci Rep 2017 Dec 21;7(1):18003. Epub 2017 Dec 21.
    Department of Applied Molecular Medicine, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951-8510, Japan.
    In maintenance hemodialysis (MHD) patients, low protein intake is associated with protein-energy wasting, a risk factor that affects outcome. However, increased protein intake may lead to hyperphosphatemia and hyperkalemia, which are also mortality risk factors. Here, we evaluated the safety and effects of purified rice endosperm protein (REP), which contains less phosphorus and potassium than soy and casein proteins, as a supplemental protein source for MHD patients. Read More

    Urinary Fractional Excretion of Phosphorus in Dogs with Spontaneous Chronic Kidney Disease.
    Vet Sci 2017 Dec 14;4(4). Epub 2017 Dec 14.
    Division of Nephrology, School of Medicine, University of São Paulo, Av. Dr. Arnaldo, 455, São Paulo, SP 01246-903, Brazil.
    The increase of urinary fractional excretion of phosphorus (uFEP) may indicate phosphorus retention before the onset of hyperphosphatemia in the early stages of chronic kidney disease (CKD). The hypothesis of this study is whether uFEP may increase during the early stage of CKD as a compensatory mechanism to prevent hyperphosphatemia as well as whether hyperphosphatemia in the late stages is associated with increase or decrease in uFEP in dogs with naturally occurring CKD; therefore, the aim of this study was to determine the uFEP in CKD dogs with different stages. Forty-nine CKD dogs were included, and they were divided into stage 1 (serum creatinine < 1. Read More

    Bone-eating kidney disease.
    SAGE Open Med Case Rep 2017 5;5:2050313X17744983. Epub 2017 Dec 5.
    Division of Nephrology, Hypertension & Renal Transplantation, University of Florida, Gainesville, FL, USA.
    In the current era of early detection of chronic kidney disease and efficient therapeutic options for management of its complications, skeletal manifestations of renal hyperparathyroidism are increasingly rare. A 31-year-old female patient presented for evaluation of severe pain in the left forearm, right hand, right knee, right hip, and lower back following a fall sustained 3 days prior to presentation. She had a history of end-stage renal disease and received maintenance hemodialysis. Read More

    Tumor Lysis Syndrome in Patients with Hematological Malignancies.
    J Oncol 2017 2;2017:9684909. Epub 2017 Nov 2.
    Department of Hematology & Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
    Tumor lysis syndrome is a metabolic complication that may follow the initiation of cancer therapy. It commonly occurs in hematological malignant patients particularly non-Hodgkin's lymphoma and acute leukemia due to chemotherapy or spontaneously. It is characterized by a biochemical abnormality such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia and its clinical outcome is directly related to these biochemical abnormalities. Read More

    High Phosphate-Induced Calcification of Vascular Smooth Muscle Cells is Associated with the TLR4/NF-κb Signaling Pathway.
    Kidney Blood Press Res 2017 8;42(6):1205-1215. Epub 2017 Dec 8.
    Background/aims: Hyperphosphatemia is one of the most notable features of chronic kidney disease (CKD). Numerous epidemiological and clinical studies have found that high serum phosphate concentrations are associated with calcification in the coronary arteries. However, the mechanisms underlying the vascular calcification induced by high phosphate have not been understood fully. Read More

    Tumor lysis syndrome with massive hyperphosphatemia and hyperuricemia.
    Clin Case Rep 2017 Dec 13;5(12):2158-2159. Epub 2017 Nov 13.
    University of FloridaGainesvilleFlorida.
    Tumor lysis syndrome (TLS) occurs when tumor cells release their contents into the bloodstream, typically in response to chemotherapy, leading to the characteristic findings of hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and acute kidney injury. Twinkle artifacts on renal ultrasound may indicate calcium phosphate deposits in such patients. Read More

    Two Cases of Lanthanum Deposition in the Stomach in the Absence of Helicobacter pylori Infection.
    Intern Med 2017 Dec 8. Epub 2017 Dec 8.
    Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
    In this case report, we describe two patients who showed a diffusely whitish mucosa in the posterior wall and the lesser curvature of the gastric body. The patients were serologically- and histopathologically-negative for Helicobacter pylori. Random biopsy specimens from the stomach revealed no regenerative changes, intestinal metaplasia, and/or foveolar hyperplasia in either of the patients. Read More

    The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.
    Clin J Am Soc Nephrol 2018 Jan 5;13(1):36-44. Epub 2017 Dec 5.
    Division of Nephrology-Hypertension, Department of Medicine and
    Background And Objectives: Niacin downregulates intestinal sodium-dependent phosphate transporter 2b expression and reduces intestinal phosphate transport. Short-term studies have suggested that niacin lowers serum phosphate concentrations in patients with CKD and ESRD. However, the long-term effects of niacin on serum phosphate and other mineral markers are unknown. Read More

    Lowering Expectations with Niacin Treatment for CKD-MBD.
    Clin J Am Soc Nephrol 2018 Jan 5;13(1):6-8. Epub 2017 Dec 5.
    Institut National de la Santé et de la Recherche Médicale U-1018, Team 5, Centre de Recherche en Epidémiologie et Santé des Populations, Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Paris-Sud University and Paris Saclay University, Villejuif, France; and.

    A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase.
    Indian J Med Paediatr Oncol 2017 Jul-Sep;38(3):360-362
    Department of Radiation Oncology, OP Jindal Institute of Cancer and Research, Hisar, Haryana, India.
    Tumor Lysis Syndrome (TLS) commonly occurs in hematological malignancies, but it is very rare in patients with a solid tumor. In cases of solid tumors, TLS usually occurs spontaneously or after the initiation of anticancer therapy, and it has a high mortality rate. This syndrome consists of a constellation of laboratory findings such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia known as laboratory TLS. Read More

    High phosphate-induced downregulation of PPARγ contributes to CKD-associated vascular calcification.
    J Mol Cell Cardiol 2018 Jan 29;114:264-275. Epub 2017 Nov 29.
    Department of Nephrology, Institute of Nephrology of Chongqing and Kidney Center of PLA, Xinqiao Hospital, Third Military Medical University, Chongqing, PR China. Electronic address:
    Medial arterial calcification associated with hyperphosphatemia is a main cause of cardiovascular mortality in patients with chronic kidney disease (CKD), but the mechanisms underlying high phosphate-induced vascular calcification remain largely unknown. Here, we observed a significant decrease in the expression of peroxisome proliferator-activated receptor-gamma (PPARγ) in calcified arteries both in CKD patients and in a mouse model of CKD with hyperphosphatemia. In vitro, high phosphate treatment led to a decreased expression of PPARγ in mouse vascular smooth muscle cells (VMSCs), accompanied by apparent osteogenic differentiation and calcification. Read More

    Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
    Am J Kidney Dis 2018 Feb 28;71(2):246-253. Epub 2017 Nov 28.
    Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN.
    Medicare costs for phosphate binders for US dialysis patients and patients with chronic kidney disease enrolled in Medicare Part D exceeded $1.5 billion in 2015. Previous data have shown that Part D costs for mineral and bone disorder medications increased faster than costs for all Part D medications for dialysis patients. Read More

    Phosphate Kinetic Models in Hemodialysis: A Systematic Review.
    Am J Kidney Dis 2018 Jan 28;71(1):75-90. Epub 2017 Nov 28.
    Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
    Background: Understanding phosphate kinetics in dialysis patients is important for the prevention of hyperphosphatemia and related complications. One approach to gain new insights into phosphate behavior is physiologic modeling. Various models that describe and quantify intra- and/or interdialytic phosphate kinetics have been proposed, but there is a dearth of comprehensive comparisons of the available models. Read More

    Association Between Klotho Gene Polymorphism and Markers of Bone Metabolism in Patients Receiving Maintenance Hemodialysis in Iran.
    Iran J Kidney Dis 2017 Nov;11(6):456-460
    Department of Clinical Biochemistry, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
    Introduction: Some genetic variations of Klotho have been reported as a risk factor for calcification and hyperphosphatemia in chronic kidney disease. Klotho polymorphism is also associated with outcome in patients receiving hemodialysis. This study aimed to evaluate the relationship between Klotho single nucleotide polymorphism (SNP) and bone metabolism as an early prognostic measure for chronic kidney disease. Read More

    Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.
    PLoS One 2017 29;12(11):e0188712. Epub 2017 Nov 29.
    Hofstra Northwell School of Medicine, Division of Medicine - Kidney Diseases and Hypertension, Great Neck, New York, United States of America.
    Two randomized, placebo-controlled trials conducted in patients with nondialysis-dependent (NDD) chronic kidney disease (CKD), iron deficiency anemia, and normal or elevated serum phosphorus demonstrated that ferric citrate (FC) significantly increased hemoglobin and decreased serum phosphate concentrations. Pooling these trial results could provide a more robust evaluation of the safety and efficacy of FC in this population. We pooled results of a phase 2 (n = 149) and 3 trial (n = 233) of patients randomized and treated for up to 12 and 16 weeks, respectively. Read More

    1 OF 69